Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Allogene Therapeutics, Inc. (ALLO)
|
Add to portfolio |
|
|
|
| Price: |
$14.49
| | Metrics |
| OS: |
167.6
|
M
| |
|
|
| Market cap: |
$2.43
|
B
| |
|
|
|
Net cash:
|
$554
|
M
| |
$3.31
|
per share
|
|
EV:
|
$1.87
|
B
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
($294)
|
M
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-05-18 |
| Revenues | 0.2 | 38.5 | 0.0 | 0.0 | 0.0 | 151.9 |
| Revenue growth | -99.4% | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 192.8 |
| Gross profit | 0.2 | 38.5 | 0.0 | 0.0 | 0.0 | -41.0 |
| Gross margin | 100.0% | 100.0% | | | | -27.0% |
| Research and development | 256.4 | 220.2 | 193.0 | 144.5 | 151.9 | |
| General and administrative | 79.3 | 74.1 | 65.3 | 57.5 | 41.0 | 41.0 |
| EBITA | -335.4 | -255.8 | -258.1 | -201.4 | -192.4 | -192.8 |
| EBITA margin | -138044.9% | -664.6% | | | | -127.0% |
| Amortization of intangibles | | | 0.2 | 0.6 | 0.5 | |
| EBIT | -335.4 | -255.8 | -258.2 | -202.0 | -192.8 | -192.8 |
| EBIT margin | -138044.9% | -664.6% | | | | -127.0% |
| Pre-tax income | -332.6 | -257.0 | -250.2 | -184.9 | -211.6 | -211.6 |
| Income taxes | 0.0 | 0.0 | 0.0 | -0.3 | -0.1 | -0.1 |
| Tax rate | 0.0% | 0.0% | 0.0% | 0.2% | 0.1% | 0.1% |
| Net income | -332.6 | -257.0 | -250.2 | -184.6 | -211.5 | -211.5 |
| Net margin | -136885.6% | -667.7% | | | | -139.3% |
| |
| Diluted EPS | ($2.32) | ($1.89) | ($2.08) | ($1.83) | ($7.31) | ($7.31) |
| Shares outstanding (diluted) | 143.1 | 135.8 | 120.4 | 101.1 | 28.9 | 28.9 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|